Olaparib Provides Substantial PFS Benefit for Ovarian Cancer

The phase III SOLO1 study found that maintenance olaparib provided a substantial progression-free survival benefit in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to research presented at the ESMO 2018 annual meeting and subsequently published in the New England Journal of Medicine. 

The international, randomized, double-blind trial evaluated maintenance olaparib in patients with high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer with a mutation in BRCA1BRCA2, or both who had a complete or partial clinical response after platinum-based chemotherapy. Patients (n=391) were randomized 2:1 to receive olaparib 300 mg twice daily (n=260) or placebo (n=131).

After a median follow-up of 41 months, the risk of disease progression or death was 70% lower with olaparib than placebo. The estimated rate of freedom from disease progression or death at 3 years was 60% in the olaparib cohort and 27% in the placebo cohort (hazard ratio = 0.30; 95% CI, 0.23-0.41; P<0.001).  

Adverse events associated with olaparib were consistent with previous reports. 

NSAID use improves ovarian cancer survival. 

Certain birth control is associated with a decreased risk of ovarian cancer.

SourceNew England Journal of Medicine